BD Bolsters Portfolio With $4.2B Cash Deal For Edwards Lifesciences' Critical Care Group: Details
Portfolio Pulse from Shivani Kumaresan
Becton, Dickinson And Company (BD) is acquiring Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. The acquisition is expected to enhance BD's portfolio and be immediately accretive to key financial measures. BD shares rose by 2.95% following the announcement.
June 03, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BD is acquiring Edwards Lifesciences' Critical Care group for $4.2 billion, enhancing its portfolio and expected to be immediately accretive to key financial measures. BD shares rose by 2.95%.
The acquisition is expected to enhance BD's portfolio and be immediately accretive to revenue growth, margins, and earnings per share. The market has reacted positively, with BD shares rising by 2.95%.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Edwards Lifesciences is selling its Critical Care group to BD for $4.2 billion. The sale will result in the cancellation of the previously announced spin-off of Critical Care.
The sale of the Critical Care group to BD for $4.2 billion will provide Edwards Lifesciences with significant cash. However, the impact on EW's stock price is neutral as the market has not shown a significant reaction.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80